Pulmonary fibrosis in systemic sclerosis: Association with myocardial fibrosis

Journal of Thoracic Imaging

Volumn 27, Issue 1, 2012, Pages 44-50

  Nicholson, Patrick J ^a   Hegarty, Christopher ^a   Jackson, Melanie ^a   Keane, David ^a   Fitzgerald, Oliver ^a   Bresnihan, Barry ^a   Veale, Douglas ^a   Dodd, Jonathan D ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

brain blood; heart diseases diagnosis pathology; magnetic resonance imaging methods; natriuretic peptide; pulmonary fibrosis; scleroderma; ventricular dysfunction

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART EJECTION FRACTION; HEART MUSCLE FIBROSIS; HUMAN; IMAGE ENHANCEMENT; LUNG FIBROSIS; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; QUALITY OF LIFE; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CONTRAST MEDIA; ENDOMYOCARDIAL FIBROSIS; FEMALE; GADOLINIUM DTPA; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PULMONARY FIBROSIS; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84855199479     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0b013e3181fbf8c1     Document Type: Article

References (34)

1. Varga JA, Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin North Am. 2008;34:115-143, vii. (Pubitemid 351329455)
2. D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428-440.
3. Goh NSL, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248-1254. 200706-877OC. (Pubitemid 351860934)
4. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford). 2006;45(suppl 4): iv14-iv17. (Pubitemid 44446757)
5. Clements PJ, Lachenbruch PA, Furst DE, et al. Cardiac score: a semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum. 1991;34:1371-1380.
6. Champion HC. The heart in scleroderma. Rheum Dis Clin North Am. 2008;34:181-190, viii. (Pubitemid 351329461)
7. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26: 384-416. (Pubitemid 40283098)
8. Tzelepis GE, Kelekis NL, Plastiras SC, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum. 2007;56:3827-3836. (Pubitemid 350100715)
9. Nassenstein K, Breuckmann F, Huger M, et al. Detection of myocardial fibrosis in systemic sclerosis by contrast-enhanced magnetic resonance imaging. Rofo. 2008;180:1054-1060.
10. Kobayashi H, Yokoe I, Hirano M, et al. Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J Rheumatol. 2009;36:106-112.
11. Hachulla A-L, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis. 2009;68:1878-1884. ard.2008.095836.
12. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102: 865-870.
13. Allanore Y, Borderie D, Meune C, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum. 2003; 48:3503-3508. (Pubitemid 37531916)
14. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581-590.
15. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215-223. (Pubitemid 32151298)
16. Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004;232:560-567. (Pubitemid 38971300)
17. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246:697-722.
18. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542. (Pubitemid 34262671)
19. Kim RJ, Shah DJ, Judd RM. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson. 2003;5: 505-514. (Pubitemid 36859434)
20. Clerico A, Iervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest. 1998;21:170-179. (Pubitemid 28223064)
21. Khanna D, Furst DE, Clements PJ, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol. 2005; 32:832-840. (Pubitemid 40676492)
22. Rannou F, Poiraudeau S, Berezne A, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum. 2007;57:94-102.
23. McCann GP, Gan CT, Beek AM, et al. Extent of MRI delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension. Am J Roent-genol. 2007;188:349-355. (Pubitemid 46167734)
24. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005;118:2-10. (Pubitemid 40082450)
25. Blyth KG, Groenning BA, Martin TN, et al. Contrast enhanced- cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J. 2005;26: 1993-1999. (Pubitemid 41435724)
26. Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26: 1461-1474. (Pubitemid 41373486)
27. Troughton RW, Richards AM. B-Type natriuretic peptides and echocardiographic measures of cardiac structure and function. J Am Coll Cardiol Img. 2009;2:216-225.
28. Martinez-Rumayor A, Richards AM, Burnett JC, et al. Biology of the natriuretic peptides. Am J Cardiol. 2008;101: 3-8.
29. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in sclero-derma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27:1485-1494. (Pubitemid 43998084)
30. Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheuma-tol Int. 2008;28:657-660.
31. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116: 2216-2233. (Pubitemid 350060359)
32. Kim RJ, Albert TS, Wible JH, et al. Performance of delayed-enhancement magnetic resonance imaging with gadoverseta-mide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation. 2008;117:629-637.
33. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100: 1992-2002. (Pubitemid 29529292)
34. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-1453.